Government Funding Exposure and Healthcare Business Value

What does government funding exposure mean in a valuation?

Government funding exposure is the share of a healthcare business's earnings that depends on a price, an eligibility rule or an incentive payment set by government rather than negotiated by the business. It is not simply having government as a customer: it is holding revenue at a price you did not set and cannot renegotiate.

It matters because most privately owned healthcare businesses are valued by capitalisation of future maintainable earnings: the profit the business can reasonably be expected to repeat under normal trading conditions, once one off, non-commercial and owner related items are removed by a process called normalisation, capitalised by applying a multiple. That multiple is the inverse of a capitalisation rate, and the rate is a judgement about risk. Funding exposure rarely changes last year's profit. It changes the confidence that the same profit is there for a buyer next year, and that confidence is most of what the multiple measures.

Market value is generally understood as the price a knowledgeable, willing but not anxious buyer would agree with an equally placed seller at arm's length, and such a buyer reads the program settings before the profit and loss. Price and value can also separate: after an unwelcome announcement, bidder numbers often fall faster than earnings.

Which funding streams actually pay the business?

Most healthcare businesses draw on more than one stream, and the streams behave differently, so a single government revenue line hides the analysis.

Medicare benefits and the MBS

Medicare benefits are paid against items in the Medicare Benefits Schedule, at a schedule fee set by government and adjusted on a published timetable. MBS Online states that from 1 July 2026 annual fee indexation applied to most general medical services items, most diagnostic imaging services and pathology items in specified groups, and that the MBS indexation factor for 1 July 2026 was 2.6 per cent. Certain attendance items by doctors without vocational training, positron emission tomography items and nuclear medicine modifier items were excluded.

So the growth rate is decided elsewhere, and some item groups are indexed while others are not: a billing line that looks uniform in the accounts can be growing at different rates underneath. Medical practice valuations covers the interaction with billing mix.

Practice incentive payments

Incentive payments sit alongside item billing and behave differently, because they are conditional. Services Australia states that Practice Incentives Program payments are made every quarter, in February, May, August and November, and that some are based on a measure of practice size called the Standardised Whole Patient Equivalent, calculated over a rolling twelve month reference period that starts sixteen months before each payment quarter and includes both Medicare Benefits Schedule and Department of Veterans' Affairs services.

Such a payment is driven by a lagging measure of activity, so it can look stable well after the activity behind it has moved, and it carries DVA exposure inside a line the practice thinks of as Medicare.

The PBS and the community pharmacy agreement

Community pharmacy remuneration is set almost entirely outside the pharmacy. The Department of Health, Disability and Ageing states that the Eighth Community Pharmacy Agreement commenced on 1 July 2024, remains in effect until 30 June 2029, and sets out the reimbursement of pharmacists for dispensing subsidised medicines and for medication management programs and services.

The same page records how quickly the settings move. From 1 January 2025 there was a one year freeze on indexation of PBS co-payments for general patients and a five year freeze for concessional patients. The optional one dollar discount is being phased out over the same period, and from 1 January 2026 the allowable discount reduced to zero for general patients and to 60 cents for concessional patients. An Addendum agreed on 12 June 2026 changed the wholesale mark-up for medicines dispensed by pharmacists from 1 July 2026 and adjusted pharmacist remuneration to offset it.

Each of those moves a different part of pharmacy income: what the patient pays at the counter, what the pharmacy may discount, and what it earns per dispense. A pharmacy valuation therefore treats script numbers and remuneration per script as separate variables, both outside the owner's control. Pharmacy valuations develops the point.

NDIS funding

NDIS revenue is exposed at three points at once: what the scheme will pay, who is eligible to receive supports, and who may deliver them. At the time of writing all three are moving.

The Department of Health, Disability and Ageing states that the National Disability Insurance Scheme Amendment (Securing the NDIS for Future Generations) Act 2026 received Royal Assent on 20 August 2026. Budgets for social, civic and community participation supports and capacity building daily activities are reset from 1 October 2026 for new plans and reassessments and from 1 February 2027 for other participants, with allocations for the first category reduced by 50 per cent and the second by 10 per cent, and critical supports such as supports in employment, home and vehicle modifications and Specialist Disability Accommodation excluded. Mandatory registration for supported independent living and platform providers rolls out from 1 July 2026 and expanded registration for higher risk supports from 1 July 2027, with all in scope providers registered by December 2030, and most providers must enrol with the National Disability Insurance Agency from 1 July 2027. From 1 October 2027 only providers on an Agency panel may deliver plan management, and from 1 July 2028 support coordination is no longer funded individually in participant plans.

That timetable does more than change prices. A provider whose mix sits in the two reduced categories faces a smaller funded pool to sell into, and for plan management and support coordination it decides whether an open market exists at all. NDIS business valuations and what reduces the value of an NDIS business take this further.

Aged care and home support funding

In home aged care the price setting question is unresolved at the time of writing, which is itself a valuation fact. The Department of Health, Disability and Ageing announced on 20 May 2026 that it would pause the implementation of price caps for Support at Home services, and that providers must continue to set reasonable prices based on the costs they incur, publish the price they most frequently charge for each service on the My Aged Care website, and keep records showing what those prices include.

The same announcement states that the Aged Care Quality and Safety Commission will be empowered to order refunds where providers are found to be overcharging, that a National Summary of Support at Home Prices will be published each quarter showing the median and the range of prices charged, and that providers are encouraged to limit price increases to no more than two a year. A home care provider therefore sets its own prices, but under a published comparison, a refund power and an expectation about repricing frequency. Aged care business valuations covers the sector position.

Workers compensation and other scheme payers

State and territory workers compensation schemes pay allied health and medical providers against published fee schedules rather than negotiated rates. WorkSafe Victoria, for example, publishes physiotherapy service fees effective from 1 July 2026 as a maximum payment rate for each item number, states that maximum fees are exclusive of GST, and marks items that require prior approval before treatment. The price is a ceiling rather than a floor, the effective date is the scheme's, and access to some items depends on the payer's approval. Physiotherapy practice valuations picks this up.

Why policy change is a valuation issue rather than background noise

The changes above are dated decisions, not hypothetical risks, and the effect of each depends on the mix a business holds. The Bulk Billing Practice Incentive Program illustrates the gain side. Services Australia states that from 1 November 2025 the program supports practices and general practitioners to provide bulk billed care, that participating practices meeting the eligibility criteria can get an additional 12.5 per cent incentive payment on every dollar of MBS benefit earned from eligible services, that the payment is distributed equally between the practice and the provider, and that participation is voluntary.

Two things follow for the entity being valued. Only the practice share reaches the practice entity, so where practitioners bill as contractors the provider share never enters the earnings being capitalised. And the payment is conditional three ways at once: the practice must bulk bill all eligible services, eligibility is assessed quarterly, and the program can be left. Earnings of that kind are not the same quality as earnings arising from patient demand, and a valuation says which is which.

Does indexation keep pace with cost growth?

A government set fee rises at a rate determined by an indexation formula, while the business's costs rise at rates set by wage decisions, rent reviews, insurance renewals, software licences and clinical consumables. Nothing connects the two, and where the fee is a ceiling, as in a workers compensation schedule, or a co-payment is frozen, as under the community pharmacy agreement, the gap cannot be recovered through price at all.

A business whose funded revenue grows slower than its cost base has a margin that declines by arithmetic rather than by mismanagement, so extrapolating the current margin forward would overstate maintainable earnings. The analysis usually tracks revenue, cost and margin per service line over several periods and asks whether the trend is a fluctuation or a structural compression. What is maintainable earnings explains how the resulting figure is framed.

Claiming, eligibility and compliance risk

Revenue already received is not always revenue finally retained, because programs carry conditions: correct item selection, valid referrals, documented eligibility, record keeping and, for some services, prior approval. The Department of Health, Disability and Ageing states that where incorrect Medicare payments are detected during a compliance audit, the Shared Debt Recovery Scheme allows a debt to be split between the health practitioner as primary debtor and the employer of the person managing the billing as secondary debtor, with a default apportionment of 65 per cent to the practitioner and 35 per cent to the employer, subject to a different split where that is fair and reasonable. The Department also states that the scheme does not apply to routine adjustments where a practitioner alerts it to an error, or to a voluntary acknowledgement of incorrect payments.

The theme runs through the other schemes: NDIS providers will need to keep records of payment and receipt of NDIS funds for seven years, with a civil penalty for failure to retain them, and in aged care the regulator is being empowered to order refunds where overcharging is found. None of this predicts anything about a particular business, but it is why due diligence asks for claiming records, and a contingent liability that cannot be sized is usually treated more conservatively than one that can be.

How a valuer treats funding exposure

Start with revenue by payer

The analysis begins with a split of revenue by payer and by program, repeated for consecutive periods so the direction is visible. Where the practice management system cannot produce it, the split is rebuilt from billing data and the valuation says so. It runs alongside patient, participant and referral concentration.

Check what the payer does to working capital

Working capital is the money tied up in the operating cycle, mainly debtors, stock and creditors, and payer mix drives it. Incentive payments made quarterly in arrears, claims unpaid until a scheme approves the service, and dispensing stock bought before it is reimbursed all lengthen that cycle, so a business can grow its funded revenue and still be short of cash while trading profitably. Program rules can also shorten the collection window itself: the Department states that from 1 December 2026 the time to make an NDIS claim for supports under a participant's plan is reduced from two years to 90 days.

Capitalising maintainable earnings measured before interest and tax produces an enterprise value, being the value of the operations before debt and surplus assets, assuming a normal level of working capital comes with the business. Where payer mix makes that level unusually high, the assumption is tested and any excess or shortfall is dealt with in the bridge to equity value, being what is left for shareholders after debt and surplus items.

Test the earnings, then decide where the answer belongs

A valuer is not in a position to predict policy, so the discipline is sensitivity analysis: model maintainable earnings on the current settings, model them again on a defined alternative such as an announced change or the loss of a conditional payment, and report the difference. That answers how much of the earnings base is at stake, not whether a change will happen.

Where a change has taken effect, has an announced start date at or near the valuation date, or where a conditional payment is no longer being earned, the adjustment usually belongs in maintainable earnings. Where the exposure is the general risk that settings may move again, it belongs in the capitalisation multiple, or in the discount rate used in a discounted cash flow, being a method that projects future cash flows and discounts them to a present value. Higher assessed risk means a higher capitalisation rate and a lower multiple.

Capitalising a single period also assumes one steady earnings stream continuing indefinitely, so it copes poorly with a scheduled step change of the kind the NDIS timetable creates. Where the dates and direction are known but earnings will sit at different levels either side of them, a discounted cash flow that models the transition years separately is often the better primary method, with capitalisation as a cross-check.

Market evidence needs the same treatment. A comparable transaction completed under earlier settings is weaker evidence than its headline suggests, because that buyer was pricing a different funding regime, so the valuation records which settings applied when it was struck. EBITDA multiples for healthcare businesses explains why the multiple carries this work.

Match the treatment to the purpose and the interest

A valuation is prepared as at a date and for a stated purpose, and funding exposure is read through both. Facts known or knowable at the valuation date belong in the analysis, so an announced change with a start date is generally in, while one first announced afterwards is generally excluded and noted as a subsequent event. That matters most where the date is fixed outside the transaction, as in a family law valuation or a tax and restructure valuation, and dates are often disputed in a shareholder dispute. The interest matters too: a minority interest, being a parcel that cannot on its own control the entity's decisions, cannot change payer mix, leave a voluntary program or renegotiate a service agreement, so exposure a controlling owner could act on is exposure a minority holder has to carry. Share and equity valuations covers that difference.

Read it through to goodwill

Goodwill is the value of the business above its identifiable net assets. Transferable, or commercial, goodwill attaches to the business and passes to a buyer; personal goodwill attaches to an individual and generally does not. Funding exposure cuts across both, because a program approval, a registration or a panel position may attach to the entity, to a premises or to a named practitioner, and may or may not survive a change of ownership. Where the right to be paid depends on something that does not transfer cleanly, the goodwill assessment says so, and net assets, being identifiable assets less liabilities, can become the more meaningful reference point. Does a medical practice have transferable goodwill develops it.

What to have ready

Four things typically shorten the analysis: revenue split by payer and program for consecutive periods, evidence of current eligibility for every conditional payment claimed, a record of which approvals or registrations attach to the entity and which to a person, and the claiming records each program requires.

Funding exposure is not a defect. It is a characteristic of most Australian healthcare businesses and it is manageable once measured. What moves value is whether it has been identified, sized and evidenced, or left for a buyer to find. What drives the value of a healthcare business sets it beside the other value drivers, and you can request a valuation to discuss a particular business.